Late-Breaking Clinical Trials – ESC Congress 2020 | European Heart Journal,

The EMPEROR-Reduced trial has shown that empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure (HF) in patients …, The EMPEROR-Reduced trial has shown that empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure (HF) in patients …, Read More

Scroll to Top